National Surveillance Network Would De-Identify Adverse Events Via 3rd Party
This article was originally published in The Gray Sheet
Executive Summary
Adverse event data would be de-identified by a third-party before submission to FDA under the agency's proposed pilot reporting system, according to Center for Devices and Radiological Health (CDRH) Office of Surveillance and Biometrics Deputy Director Susan Gardner.